April 16, 2008 - Medicure Inc. (TSX:MPH)(AMEX:MCU), a cardiovascular-focused biopharmaceutical company, announced that the positive results from the Phase II MATCHED study, which evaluated the combination of MC-1 and lisinopril in patients with coexisting type II diabetes and hypertension, will be presented at the Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) Annual Conference 2008 in Atlanta, GA... Medicure's Press Release -
Showing posts with label Medicure. Show all posts
Showing posts with label Medicure. Show all posts
Monday, April 21, 2008
Medicure : Presentation of Phase II Matched Results at Cardiovascular Conference
April 16, 2008 - Medicure Inc. (TSX:MPH)(AMEX:MCU), a cardiovascular-focused biopharmaceutical company, announced that the positive results from the Phase II MATCHED study, which evaluated the combination of MC-1 and lisinopril in patients with coexisting type II diabetes and hypertension, will be presented at the Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) Annual Conference 2008 in Atlanta, GA... Medicure's Press Release -
Subscribe to:
Posts (Atom)
